|Previous Section||Index||Home Page|
26 Jun 2008 : Column 518Wcontinued
|As at: 21 April 2008||Scoping a possible audit||Tendering in progress||In development or piloting||Recruiting/running|
Coronary interventions (eg angioplasty, opening up heart artery)
ACP Association of Coloproctologists of Great Britain and Ireland, ASA Ambulance Services Association, AUGIS Association of Upper GI Surgeons, BAHNO British Association of Head and Neck Oncologists, BCIS British Cardiac Intervention Society, BOA British Orthopaedic Association, BSH British Society for Heart Failure, HRUK Heart Rhythm UK, NCD National Clinical Director, NCASP National Clinical Audit Support Programme (part of Health and Social Care Information Centre, HSCIC), RA Renal Association, RCNI Royal College of Nursing Institute, RCP Royal College of Psychiatrists, RCPCH Royal College of Paediatrics and Child Health, RCPsychiat Royal College of Psychiatrists, SCTS Society for Cardiothoracic Surgery, UCLH University College Hospital London, Univ. Birm. University of Birmingham Department of Primary Care and General Practice, VSGBI Vascular Society of Great Britain and Ireland.
Mr. Lansley: To ask the Secretary of State for Health what the evidential basis is for the statement in the impact assessment on the statutory scheme to control prices of branded NHS medicines that any change in UK pricing will have a negligible effect on the viability of these global businesses. 
Dawn Primarolo: The Department's Consultation on a Statutory Scheme to Control the Price of Branded NHS Medicines and the accompanying impact assessment, issued on 18 June 2008, set out how the proposed measures that are subject to consultation are estimated to result in a lost profits to the pharmaceutical industry of £280 million a year. The United Kingdom comprises only 3.5 per cent. of the global market and in patent medicine prices will continue to be significantly greater than manufacturing and distribution costs. Therefore the Department has concluded that, although there will be an impact on profits for the global pharmaceutical industry as a result of the proposed measures, these will not be significant enough to affect the viability of global pharmaceutical companies.
The part of the consultation dealing with the price cut and measures to limit the price of out of patent brands ends on 25 September 2008. The consultation document invites comments on the impact assessment, in particular the analysis of costs and benefits. Copies of Consultation on a Statutory Scheme to Control the Price of Branded NHS Medicines have been placed in the Library and are also available on the Department's website at:
Mr. Lansley: To ask the Secretary of State for Health on what date he expects to announce funding allocations for the NHS for 2009-10. 
Mr. Bradshaw: A specified date has yet to be confirmed for revenue allocations to primary care trusts for 2009-10 and 2010-11 but the intention is that this will be announced before the summer recess.
Norman Lamb: To ask the Secretary of State for Health how many (a) primary care trusts and (b) strategic health authorities have a medical director in post. 
Ann Keen: This information is not collected centrally. The non-medical census which collects data on numbers includes directors within the 'senior managers' category but this is not sub-divided in more detail.
Norman Lamb: To ask the Secretary of State for Health what guidelines exist on the appointment of medical directors to (a) primary care trusts and (b) strategic health authorities. 
Ann Keen: There is currently no departmental guidance on the appointment of medical directors to primary care trusts and strategic health authorities.
Norman Lamb: To ask the Secretary of State for Health how many physicians' assistants are in post in each (a) primary care trust and (b) hospital trust. 
Ann Keen: The information is not collected centrally.
The role of physicians' assistant is a new role and is not identified as a separate staff group in the national health service workforce census.
Norman Lamb: To ask the Secretary of State for Health how many physicians' assistants in England (a) were in training and (b) completed their training in each of the last three years. 
Ann Keen: This information was not collected prior to the 2007-08 financial year. The final figures for 2007-08 will be available later in the summer.
Norman Lamb: To ask the Secretary of State for Health what guidelines exist within the NHS for the management of NHS staff with mental health problems. 
Ann Keen: The healthy workplaces handbook is produced by NHS Employers, who represent trusts in England on workforce issues. The handbook includes a section on mental health and employment, which provides national health service managers and occupational health professionals with the tools they need to assess the suitability of persons having mental health problems who wish to work or train, or who are already working in the service.
Norman Lamb: To ask the Secretary of State for Health what estimate he has made of the annual cost to the NHS of mental health problems experienced by NHS staff. 
Ann Keen: This information is not held centrally.
Mr. Stephen O'Brien:
To ask the Secretary of State for Health pursuant to the Answer of 3 June 2008,
Official Report, columns 910-11W, on the NHS: personal records, if he will break down the number of nutrition-related adverse incidents reported to the National Reporting and Learning System by area of incident. 
Ann Keen: The following table shows a list of nutrition-related adverse incidents reported to the National Reporting and Learning System by each strategic health authority (SHA) area.
|Next Section||Index||Home Page|